MAZE THERAPEUTICS, INC. Line of Credit Facility, Interest Rate During Period
MAZE THERAPEUTICS, INC. (MAZE) reported Line of Credit Facility, Interest Rate During Period of 4.50% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Debt
us-gaap:LineOfCreditFacilityInterestRateDuringPeriod · last filed 2026-03-25
- MAZE THERAPEUTICS, INC. line of credit facility, interest rate during period for the quarter ending 2025-03-31 was 4.50%.
| Period end | Line of Credit Facility, Interest Rate During Period 1 month | Line of Credit Facility, Interest Rate During Period 3 month | Line of Credit Facility, Interest Rate During Period 6 month | Line of Credit Facility, Interest Rate During Period 9 month |
|---|---|---|---|---|
| 2025-09-30 | 4.50% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.50% 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 4.50% 10-K · filed 2026-03-25 | 4.50% 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |